Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 2 Trial. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), s446. https://doi.org/10.25251/skin.8.supp.446